Molecular biomarkers for aflatoxins and their application to human liver cancer

Peter Scholl, Steven M. Musser, Thomas W. Kensler, John D. Groopman

Research output: Contribution to journalArticle

Abstract

The rationale for developing molecular biomarkers to monitor and assess risk from human exposure to aflatoxins have been justified by the association of these carcinogens with human liver cancer, a disease that causes at least 250000 deaths world-wide each year. The goal of our research has been the development of aflatoxin biomarkers based upon the knowledge of the biochemistry and toxicology of aflatoxins gleaned from both experimental and human studies. These biomarkers have been subsequently utilized in experimental chemoprotection models to provide data on the modulation of these markers under different situations of disease risk. Several of the aflatoxin specific biomarkers have been validated in epidemiologic studies and are now available to use as intermediate biomarkers in chemoprotection trials. This systematic approach provides encouragement for preventive interventions and should serve as a template for the development, validation and application of other chemical-specific biomarkers to cancer or other chronic diseases.

Original languageEnglish (US)
Pages (from-to)S171-S176
JournalPharmacogenetics
Volume5
DOIs
StatePublished - Dec 1995

ASJC Scopus subject areas

  • Genetics
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Molecular biomarkers for aflatoxins and their application to human liver cancer'. Together they form a unique fingerprint.

  • Cite this